Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.55
BCR's Cash-to-Debt is ranked lower than
65% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. BCR: 0.55 )
Ranked among companies with meaningful Cash-to-Debt only.
BCR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.72 Max: 4.5
Current: 0.55
0.08
4.5
Equity-to-Asset 0.32
BCR's Equity-to-Asset is ranked lower than
80% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. BCR: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
BCR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.55 Max: 0.76
Current: 0.32
0.3
0.76
Interest Coverage 17.39
BCR's Interest Coverage is ranked lower than
60% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 39.88 vs. BCR: 17.39 )
Ranked among companies with meaningful Interest Coverage only.
BCR' s Interest Coverage Range Over the Past 10 Years
Min: 15.05  Med: 23.74 Max: 60.49
Current: 17.39
15.05
60.49
Piotroski F-Score: 8
Altman Z-Score: 4.28
Beneish M-Score: -2.27
WACC vs ROIC
5.40%
33.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 25.51
BCR's Operating Margin % is ranked higher than
91% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.65 vs. BCR: 25.51 )
Ranked among companies with meaningful Operating Margin % only.
BCR' s Operating Margin % Range Over the Past 10 Years
Min: 18.91  Med: 25.4 Max: 39.79
Current: 25.51
18.91
39.79
Net Margin % 14.31
BCR's Net Margin % is ranked higher than
82% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. BCR: 14.31 )
Ranked among companies with meaningful Net Margin % only.
BCR' s Net Margin % Range Over the Past 10 Years
Min: 3.96  Med: 17.46 Max: 22.62
Current: 14.31
3.96
22.62
ROE % 33.30
BCR's ROE % is ranked higher than
95% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.98 vs. BCR: 33.30 )
Ranked among companies with meaningful ROE % only.
BCR' s ROE % Range Over the Past 10 Years
Min: 8.19  Med: 22.49 Max: 33.78
Current: 33.3
8.19
33.78
ROA % 10.26
BCR's ROA % is ranked higher than
82% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.97 vs. BCR: 10.26 )
Ranked among companies with meaningful ROA % only.
BCR' s ROA % Range Over the Past 10 Years
Min: 2.73  Med: 14.07 Max: 17.1
Current: 10.26
2.73
17.1
ROC (Joel Greenblatt) % 89.13
BCR's ROC (Joel Greenblatt) % is ranked higher than
94% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.87 vs. BCR: 89.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BCR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 53.37  Med: 81.73 Max: 148.85
Current: 89.13
53.37
148.85
3-Year Revenue Growth Rate 9.30
BCR's 3-Year Revenue Growth Rate is ranked higher than
69% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.20 vs. BCR: 9.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BCR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.5  Med: 10.4 Max: 13.9
Current: 9.3
0.5
13.9
3-Year EBITDA Growth Rate -10.70
BCR's 3-Year EBITDA Growth Rate is ranked lower than
80% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. BCR: -10.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BCR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -18.9  Med: 9.9 Max: 25.4
Current: -10.7
-18.9
25.4
3-Year EPS without NRI Growth Rate -5.70
BCR's 3-Year EPS without NRI Growth Rate is ranked lower than
67% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. BCR: -5.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BCR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -34  Med: 10.8 Max: 28.9
Current: -5.7
-34
28.9
GuruFocus has detected 4 Warning Signs with C.R. Bard Inc $BCR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BCR's 10-Y Financials

Financials (Next Earnings Date: 2017-04-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BCR Guru Trades in Q1 2016

Joel Greenblatt 150,877 sh (+1864.03%)
Ray Dalio 23,315 sh (+116.16%)
Paul Tudor Jones 225,900 sh (+45.76%)
Jim Simons 1,355,300 sh (+23.38%)
Tom Gayner 9,000 sh (unchged)
Yacktman Fund 900,000 sh (unchged)
Yacktman Focused Fund 140,000 sh (unchged)
Vanguard Health Care Fund Sold Out
John Hussman Sold Out
Donald Yacktman 1,276,894 sh (-0.53%)
Jeremy Grantham 69,375 sh (-33.34%)
Pioneer Investments 289,215 sh (-35.16%)
» More
Q2 2016

BCR Guru Trades in Q2 2016

Louis Moore Bacon 904 sh (New)
Tom Gayner 9,000 sh (unchged)
Jeremy Grantham Sold Out
Yacktman Focused Fund Sold Out
Pioneer Investments 289,061 sh (-0.05%)
Ray Dalio 20,815 sh (-10.72%)
Jim Simons 1,063,200 sh (-21.55%)
Yacktman Fund 650,000 sh (-27.78%)
Donald Yacktman 806,300 sh (-36.85%)
Joel Greenblatt 5,582 sh (-96.30%)
Paul Tudor Jones 1,100 sh (-99.51%)
» More
Q3 2016

BCR Guru Trades in Q3 2016

Steven Cohen 229,200 sh (New)
Jeremy Grantham 98,050 sh (New)
Paul Tudor Jones 126,800 sh (+11427.27%)
Louis Moore Bacon 2,426 sh (+168.36%)
Tom Gayner Sold Out
Pioneer Investments 271,837 sh (-5.96%)
Donald Yacktman 738,964 sh (-8.35%)
Yacktman Fund 550,000 sh (-15.38%)
Jim Simons 797,200 sh (-25.02%)
Joel Greenblatt 3,760 sh (-32.64%)
Ray Dalio 6,915 sh (-66.78%)
» More
Q4 2016

BCR Guru Trades in Q4 2016

George Soros 900 sh (New)
Joel Greenblatt 50,845 sh (+1252.26%)
Steven Cohen 382,200 sh (+66.75%)
Yacktman Fund 550,000 sh (unchged)
Ray Dalio Sold Out
Donald Yacktman 723,901 sh (-2.04%)
Jeremy Grantham 95,867 sh (-2.23%)
Jim Simons 509,400 sh (-36.10%)
Paul Tudor Jones 75,000 sh (-40.85%)
Pioneer Investments 31,481 sh (-88.42%)
» More
» Details

Insider Trades

Latest Guru Trades with BCR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:OTCPK:CLPBY, NAS:XRAY, OTCPK:OCPNY, NYSE:MTD, NYSE:WAT, OTCPK:TRUMF, NAS:HOLX, NAS:ILMN, NYSE:RMD, NYSE:COO, OTCPK:ESLOY, NYSE:BAX, OTCPK:SAUHY, NYSE:WST, NYSE:STE, NYSE:HRC, OTCPK:GNGBY, NYSE:CMD, NAS:ICUI, OTCPK:ANSLY » details
Traded in other countries:BR6.Germany,
CR Bard Inc manufactures, distributes and sells medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, and extended care facilities.

C.R. Bard designs, manufactures, and markets a wide range of medical, diagnostic, and surgical devices that are primarily intended for one-time use. The firm enjoys a sizable footprint in key therapeutic areas, including urology, oncology, peripheral vascular solutions, soft tissue surgery, breast biopsy and reconstruction. Sales to foreign countries account for approximately one third of total revenue.

Guru Investment Theses on C.R. Bard Inc

Donald Yacktman Comments on C.R. Bard - Nov 05, 2015

C.R. Bard (NYSE:BCR) was a solid performer in the third quarter. As a result, we reduced the Fund’s position size in Bard.

From Donald Yacktman (Trades, Portfolio)'s third quarter 2015 commentary.

Check out Donald Yacktman latest stock trades

Top Ranked Articles about C.R. Bard Inc

Tom Gayner Sells 5 Holdings, Reduces 1 Other An overview of the guru's 3rd quarter sales
Tom Gayner (Trades, Portfolio) is co-CEO of Markel Corp., and president and chief investment officer of Markel-Gayner Asset Management. During the third quarter, the guru reduced or exited the following holdings: Read more...
Timothy Ring, CEO and Chairman of C.R. Bard Inc., Sold 92,293 Shares of the Company on Sept. 28 Insider buy
Timothy Ring (Insider Trades), CEO and Chairman of C.R. Bard Inc. (BCR), sold 92,293 shares of the company on Sept. 28, 2016. The average price per share was $227.81, for a total transaction of $21,025,268. C.R. Bard, a multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in vascular, urology, oncology and surgical specialty products, has a market cap of $16.47 billion. Read more...
Insider Trades: C.R. Bard, NVIDIA and Alphabet Largest insider trades of the week
The All-in-One Screener can be used to find insider buys and sells over the last week by clicking on the "Insiders" tab and changing the settings for All Insider Buys to “200,000sh+” duration to "September 2016” and “September 2016” and All Insider Sales to “$5,000,000+”. Read more...
Yacktman Fund Hopeful After Second Quarter Report Fund comments on PepsiCo, Fox
The AMG Yacktman Fund (Trades, Portfolio) (YACKX) gave their second quarter update on July 27. Joe Maccone from Affiliated Managers Group Fund (AMG) moderated the meeting. Stephen Yacktman and Jason Subotky, the portfolio managers at Yacktman Asset Management, gave their views on the portfolio’s performance as well as discussed their major stock purchases and sales. Read more...
The Yacktman Focused Fund Sells Out of C.R. Bard Inc. C.R. Bard reached its 52-week high during the second quarter
During the second quarter, the Yacktman (Trades, Portfolio) Focused Fund sold out its remaining 140,000 shares of C.R Bard (NYSE:BCR) at at an average price of $216.98. The Yacktman (Trades, Portfolio) Focused Fund saw a 66% increase in its investment in C.R. Bard Inc. since the first quarter of 2011. Read more...
5 Companies Achieve 52-Week Highs C.R. Bard, Tim Hortons, Thermo Fisher, Fiserv, Molson Coors reach landmarks
According to GuruFocus list of 52-week highs, these guru stocks have reached their 52-week highs. Read more...

Ratios

vs
industry
vs
history
PE Ratio 35.42
BCR's PE Ratio is ranked lower than
61% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.61 vs. BCR: 35.42 )
Ranked among companies with meaningful PE Ratio only.
BCR' s PE Ratio Range Over the Past 10 Years
Min: 14.25  Med: 24.37 Max: 154.75
Current: 35.42
14.25
154.75
Forward PE Ratio 21.46
BCR's Forward PE Ratio is ranked higher than
70% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.75 vs. BCR: 21.46 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 35.42
BCR's PE Ratio without NRI is ranked lower than
60% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.85 vs. BCR: 35.42 )
Ranked among companies with meaningful PE Ratio without NRI only.
BCR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 14.25  Med: 24.07 Max: 154.75
Current: 35.42
14.25
154.75
Price-to-Owner-Earnings 151.29
BCR's Price-to-Owner-Earnings is ranked lower than
88% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.68 vs. BCR: 151.29 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BCR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.25  Med: 25.16 Max: 434.61
Current: 151.29
12.25
434.61
PB Ratio 10.94
BCR's PB Ratio is ranked lower than
87% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.38 vs. BCR: 10.94 )
Ranked among companies with meaningful PB Ratio only.
BCR' s PB Ratio Range Over the Past 10 Years
Min: 3.22  Med: 4.74 Max: 11.02
Current: 10.94
3.22
11.02
PS Ratio 5.05
BCR's PS Ratio is ranked lower than
71% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.85 vs. BCR: 5.05 )
Ranked among companies with meaningful PS Ratio only.
BCR' s PS Ratio Range Over the Past 10 Years
Min: 2.56  Med: 3.61 Max: 5.08
Current: 5.05
2.56
5.08
Price-to-Free-Cash-Flow 42.07
BCR's Price-to-Free-Cash-Flow is ranked lower than
70% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.12 vs. BCR: 42.07 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BCR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.1  Med: 17.54 Max: 49.36
Current: 42.07
10.1
49.36
Price-to-Operating-Cash-Flow 34.28
BCR's Price-to-Operating-Cash-Flow is ranked lower than
82% of the 97 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.55 vs. BCR: 34.28 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BCR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.09  Med: 14.96 Max: 40.02
Current: 34.28
9.09
40.02
EV-to-EBIT 26.10
BCR's EV-to-EBIT is ranked lower than
62% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.23 vs. BCR: 26.10 )
Ranked among companies with meaningful EV-to-EBIT only.
BCR' s EV-to-EBIT Range Over the Past 10 Years
Min: 8  Med: 15.85 Max: 49.4
Current: 26.1
8
49.4
EV-to-EBITDA 20.12
BCR's EV-to-EBITDA is ranked lower than
59% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.75 vs. BCR: 20.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
BCR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.2  Med: 13.3 Max: 31.5
Current: 20.12
7.2
31.5
PEG Ratio 15.43
BCR's PEG Ratio is ranked lower than
100% of the 55 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.82 vs. BCR: 15.43 )
Ranked among companies with meaningful PEG Ratio only.
BCR' s PEG Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.62 Max: 39.28
Current: 15.43
0.94
39.28
Shiller PE Ratio 47.70
BCR's Shiller PE Ratio is ranked lower than
54% of the 46 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 43.77 vs. BCR: 47.70 )
Ranked among companies with meaningful Shiller PE Ratio only.
BCR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.39  Med: 30.56 Max: 48.19
Current: 47.7
23.39
48.19
Current Ratio 2.09
BCR's Current Ratio is ranked lower than
60% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. BCR: 2.09 )
Ranked among companies with meaningful Current Ratio only.
BCR' s Current Ratio Range Over the Past 10 Years
Min: 1.5  Med: 2.4 Max: 5.3
Current: 2.09
1.5
5.3
Quick Ratio 1.65
BCR's Quick Ratio is ranked higher than
51% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. BCR: 1.65 )
Ranked among companies with meaningful Quick Ratio only.
BCR' s Quick Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.84 Max: 4.25
Current: 1.65
0.92
4.25
Days Inventory 122.12
BCR's Days Inventory is ranked higher than
54% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.59 vs. BCR: 122.12 )
Ranked among companies with meaningful Days Inventory only.
BCR' s Days Inventory Range Over the Past 10 Years
Min: 99.01  Med: 105.62 Max: 122.12
Current: 122.12
99.01
122.12
Days Sales Outstanding 46.91
BCR's Days Sales Outstanding is ranked higher than
80% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.07 vs. BCR: 46.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
BCR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.91  Med: 59 Max: 63.66
Current: 46.91
46.91
63.66
Days Payable 25.54
BCR's Days Payable is ranked lower than
88% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 49.88 vs. BCR: 25.54 )
Ranked among companies with meaningful Days Payable only.
BCR' s Days Payable Range Over the Past 10 Years
Min: 18.23  Med: 20.88 Max: 28.74
Current: 25.54
18.23
28.74

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.41
BCR's Dividend Yield % is ranked lower than
87% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.25 vs. BCR: 0.41 )
Ranked among companies with meaningful Dividend Yield % only.
BCR' s Dividend Yield % Range Over the Past 10 Years
Min: 0.4  Med: 0.68 Max: 0.9
Current: 0.41
0.4
0.9
Dividend Payout Ratio 0.14
BCR's Dividend Payout Ratio is ranked higher than
82% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. BCR: 0.14 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BCR' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.15 Max: 0.52
Current: 0.14
0.1
0.52
3-Year Dividend Growth Rate 6.80
BCR's 3-Year Dividend Growth Rate is ranked lower than
65% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.10 vs. BCR: 6.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BCR' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 3.2  Med: 5.7 Max: 7.4
Current: 6.8
3.2
7.4
Forward Dividend Yield % 0.42
BCR's Forward Dividend Yield % is ranked lower than
90% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. BCR: 0.42 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.55
BCR's 5-Year Yield-on-Cost % is ranked lower than
82% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. BCR: 0.55 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BCR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.54  Med: 0.91 Max: 1.2
Current: 0.55
0.54
1.2
3-Year Average Share Buyback Ratio 1.70
BCR's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. BCR: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BCR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.7  Med: 1.7 Max: 5.3
Current: 1.7
-0.7
5.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.24
BCR's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
54% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.04 vs. BCR: 2.24 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BCR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.91  Med: 1.58 Max: 2.25
Current: 2.24
0.91
2.25
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.31
BCR's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
75% of the 28 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.07 vs. BCR: 3.31 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.40
BCR's Price-to-Median-PS-Value is ranked lower than
70% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. BCR: 1.40 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BCR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.41  Med: 0.87 Max: 1.4
Current: 1.4
0.41
1.4
Earnings Yield (Greenblatt) % 3.83
BCR's Earnings Yield (Greenblatt) % is ranked higher than
60% of the 230 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.20 vs. BCR: 3.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BCR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2  Med: 6.3 Max: 12.5
Current: 3.83
2
12.5
Forward Rate of Return (Yacktman) % 5.86
BCR's Forward Rate of Return (Yacktman) % is ranked lower than
64% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.56 vs. BCR: 5.86 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BCR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 5.8  Med: 17.3 Max: 22.8
Current: 5.86
5.8
22.8

More Statistics

Revenue (TTM) (Mil) $3,714
EPS (TTM) $ 7.03
Beta0.44
Short Percentage of Float2.46%
52-Week Range $198.60 - 252.25
Shares Outstanding (Mil)72.31

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,889 4,099 4,219
EPS ($) 11.63 6.67 13.93
EPS without NRI ($) 11.63 6.67 13.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.18%
Dividends per Share ($) 1.02 1.22 1.34
» More Articles for BCR

Headlines

Articles On GuruFocus.com
Tom Gayner Sells 5 Holdings, Reduces 1 Other Dec 22 2016 
Dividend Aristocrats in Focus Part 25: CR Bard Nov 01 2016 
Timothy Ring, CEO and Chairman of C.R. Bard Inc., Sold 92,293 Shares of the Company on Sept. 28 Oct 01 2016 
Insider Trades: C.R. Bard, NVIDIA and Alphabet Sep 30 2016 
The Yacktman Focused Fund Sells Out of C.R. Bard Inc. Jul 19 2016 
5 Stocks Hit 52-Week High Prices Jul 11 2016 
5 Companies Have Hit 52-Week Highs Jun 21 2016 
5 Companies Achieve 52-Week Highs Jun 07 2016 
Dividends’ True Contribution to Total Return May Surprise You Mar 24 2016 
Medical Products Company CR Bard Has Stable Business Mar 09 2016 

More From Other Websites
Zacks.com featured highlights: East West Bancorp, CBRE Group, Colliers International Group, C.R.... Mar 21 2017
C.R. Bard, Inc. (New Jersey) : BCR-US: Dividend Analysis : January 23rd, 2017 (record date) : By the... Mar 16 2017
New highs for the CNBC IQ 100 Mar 13 2017
C. R. Bard (BCR) Well Poised for Growth, Macro Woes Remain Mar 09 2017
C.R. Bard, Inc. (New Jersey) :BCR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 8, 2017 Mar 08 2017
Bard to Present at Barclays Global Healthcare Conference Mar 07 2017
C.R. Bard (BCR) Up 8.2% Since Earnings Report: Can It Continue? Mar 02 2017
Go With the Upside on C.R. Bard Feb 27 2017
Bard to Present at Cowen and Company Healthcare Conference Feb 27 2017
BARD C R INC /NJ/ Financials Feb 17 2017
BARD C R INC /NJ/ Files SEC form 10-K, Annual Report Feb 13 2017
The Zacks Analyst Blog Highlights: C. R. Bard, Illinois Tool Works, Sherwin-Williams, Cintas and S&P... Feb 03 2017
ETFs with exposure to C.R. Bard, Inc. (New Jersey) : February 2, 2017 Feb 02 2017
C. R. Bard (BCR): Moving Average Crossover Alert Feb 01 2017
C.R. Bard, Inc. (New Jersey) :BCR-US: Earnings Analysis: 2016 By the Numbers : January 30, 2017 Jan 30 2017
C.R. Bard (BCR) Q4 Earnings & Sales Better Than Expected Jan 27 2017
C R Bard Inc Earnings Call scheduled for 5:00 pm ET today Jan 26 2017
C.R. Bard tops Street 4Q forecasts Jan 26 2017
C.R. Bard tops Street 4Q forecasts Jan 26 2017
BARD C R INC /NJ/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jan 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)